ABCL news

Phase 2 trial of ABCL635 met primary endpoints for hot flash reduction. The results mark a new efficacy benchmark for the treatment of vasomotor symptoms.

AbCellera Biologics will release Phase 2 trial data for ABCL635 on Monday, August 10, 2026. This potential first-in-class antibody for menopause symptoms is expected to drive investor attention and market speculation regarding the company's pipeline valuations.

AbCellera announced $4.1M in total revenue and expanded its T-cell engager platform with new multi-billion dollar collaborations to Jazz and Vertex. With over $675M in liquidity, the company also expects top-line data from its ABCL635 study to be read out shortly.

AbCellera collaborated with Vertex Pharmaceuticals to develop multispecific T-cell engagers, receiving $28.1 million in upfront payments. The deal strengthens AbCellera's position in the advanced autoimmune and immunology markets.

AbCellera Biologics appointed Dr. Lynn Seely as an independent director. Seely's biopharmaceutical experience may bolster the company's strategic leadership.

Jazz Pharmaceuticals and AbCellera announced a collaboration to discover next-generation T-cell engaging multispeci​fic antibodies, with Jazz paying $56 million upfront and eligible for up to $792 million in milestone payments per program. The partnership expands Jazz's oncology focus on gastrointes…

AbCellera appointed Dr. Victor Sandor, an experienced medical oncologist and former CMO at Array BioPharma, to its Board of Directors. The appointment strengthens the company's leadership as it advances its antibody discovery pipeline toward clinical outcomes.